



# Cancer Epigenetics

Peter W. Laird


**USC Epigenome Center**

USC/Norris Comprehensive Cancer Center

Keck School of Medicine


University of Southern California

# DNA Methylation Alterations in Cancer




- CpG Islands may acquire abnormal hypermethylation in cancer
- Methylated CpG Island promoters are transcriptionally silenced in cancer
- Areas of low-CpG density may lose DNA methylation in cancer

# Epigenetic Silencing of *BRCA1* in Serous Ovarian Cancer




- Red: Fallopian Tubes
- Purple – Somatic Mutation
- Green – Germline Mutation
- Blue – Epigenetic Silencing
- Hollow – Not Sequenced





# Outline

- **CpG Island Methylator Phenotypes - Glioblastoma**


# Glioma-CpG Island Methylator Phenotype (G-CIMP) (TCGA)



# G-CIMP Is a Subset of Proneural Glioblastomas with Better Survival



# Glioma-CpG Island Methylator Phenotype (G-CIMP) (TCGA)




**G-CIMP is Tightly Linked to *IDH1* Mutation**

ALL TUMORS		G-CIMP		TOTAL
		—	+	
IDH1	Wild-type	184	5	189
	Mutant	0	18	18
TOTAL		184	23	207

# Model for G-CIMP

*IDH1* Mutation Causes Aberrant CpG Island Methylation




*.....Does not explain G-CIMP IDH1<sup>wt</sup> cases*




# Outline

- **CpG Island Methylator Phenotypes - Glioblastoma**
- **Cross-tumor Comparisons**

# Comparison of 2,275 TCGA Cancer Samples and 409 Normal Tissues





# Outline

- **CpG Island Methylator Phenotypes - Glioblastoma**
- **Cross-tumor Comparisons**
- **Bisulfite Sequencing - Epigenetic Origins of Cancer**





# TCGA Whole Genome Bisulfite Sequencing (WGBS)

TCGA Sample	Type	Description	Bisulfite non-conversion	Mean cvg	# CpGs	1x cvg (% CpGs)	5x cvg (% CpGs)
AA-3518-01A	COAD	MSI-H	0.92%	23x	51.8M	92%	90%
AA-3518-11A	COAD - N		0.86%	22x	51.5M	91%	90%
A7-A0CE-01A	BRCA	Basal-like subtype	0.31%	19x	50.7M	90%	86%
A7-A0CE-11A	BRCA - N		0.36%	19x	50.3M	89%	85%
AA-3518-01A	UCEC	Grade 1 endometrioid	0.31%	19x	52.1M	92%	90%
AA-3518-11A	UCEC - N		0.31%	18x	51.8M	92%	89%
60-2722-01A	LUSC	Classical subtype	0.30%	21x	51.8M	92%	89%
60-2722-11A	LUSC - N		0.61%	5x	39.3M	69%	33%


- In Production: 3 Lung squamous Tumors, 3 Breast Tumors
- In Sample Selection: 2 GBM Tumors, 3 Renal Cell Kidney Pairs

# Whole Genome Bisulfite Sequencing of TCGA Tumors and Normal Tissues

MP:  
Methylation  
Prone  
Regions



# Methylation-Prone Elements are Enriched for Stem-Cell Polycomb Marks




ENCODE chromatin types from J. Ernst *et al. Nature* 2011

- Active promoter: K4me3, K9ac, K27ac
- Weak promoter: K4me3, K9ac
- Poised promoter: K4me1/2, K27me3

- Strong enhancer: K4me1/2, K9ac, K27ac
- Weak enhancer: K4me1/2
- CTCF Insulator: CTCF

# Transcriptional Potential Associated with Histone H3 Methylation




## Polycomb Target Genes in Embryonic Stem Cells:


- Master regulators of differentiation and development
- Poised to be turned on during differentiation
- Bivalent epigenetic state: Active (H3K4me3) and Repressive Marks (H3K27Me3)



# Polycomb Target DNA Methylation Starts in Normal Tissues



# Model: Polycomb Crosstalk Leads to Cumulative Stochastic Methylation




# This Model....

- **Would explain the DNA methylation behavior for about half of cancer-specifically methylated genes**
- **Is consistent with the observation of epigenetic field effects adjacent to tumors**
- **Is consistent with the stem-cell like behavior of cancer cells and with the evidence for tumor-initiating cells**
- **Suggests that therapeutic cloning strategies using human ES cells or IPS cells should incorporate screening for PRC2 DNA methylation abnormalities**
- **Suggests that the first steps of oncogenesis may be epigenetic**

# Outline

- **CpG Island Methylator Phenotypes - Glioblastoma**
- **Cross-tumor Comparisons**
- **Bisulfite Sequencing - Epigenetic Origins of Cancer**
- **Bisulfite Sequencing – Long Range Instability**

# Methylation-Prone CpG Islands




# Regions of Focal Hypermethylation and Long-Range Hypomethylation Coincide




# A Subset of the Cancer Epigenome Has Partially Lost Methylation

20-kb Windows



# Regions of Focal Hypermethylation and Long-Range Hypomethylation Coincide





# Outline

- **CpG Island Methylator Phenotypes - Glioblastoma**
- **Cross-tumor Comparisons**
- **Bisulfite Sequencing - Epigenetic Origins of Cancer**
- **Bisulfite Sequencing – Long Range Instability**
- **Bisulfite Sequencing – Nuclear Architecture**

# Hypomethylated “Oceans” Correspond to Lamin Attachment Domains

Part of Chromosome 3q

Genes

CpG Islands

ES-Cell Methylation

Normal Colon Methylation

Colon Tumor Methylation

Hypermethylated in Cancer

Hypomethylated in Cancer

non-TCGA Colon PMD

TCGA COAD PMD

TCGA UCEC PMD

TCGA BRCA PMD

TCGA LUSC PMD


IMR90 PMD

Nuclear Lamina-Associated

Non-Lamina-Associated

# Spatial Organization of the Epigenome

- Lamin Attachment
- Late Replication
- Epigenetic Instability in Cancer



Bas Van Steensel,  
*Curr Opin Cell Biol* 2010

- Active Transcription
- Epigenetically Stable in Cancer

# SUMMARY

## Epigenetic Subtypes

- CpG Island Methylator Phenotype in Glioblastoma – *IDH1* Mutation

## Epigenetic Origins of Cancer

- Polycomb Repressor Binding in ES-Cells Predisposes to Aberrant DNA Methylation in Cancer
- Polycomb Repressor Predisposition Seen Across Cancer Types

## The Role of Nuclear Architecture in Epigenetic Instability

- Focal Hypermethylation and Long-Range Hypomethylation Coincide in Partially Methylated Domains (PMDs)
- Epigenetically Unstable PMDs are Associated with Nuclear Lamina Attachment and Late-Replicating Regions

# Acknowledgements

## USC EPIGENOME CENTER

**Dan Weisenberger**

**Ben Berman**

**Houtan Noushmehr**

**Toshi Hinoue**

**Hui Shen**

**Tim Triche Jr.**

**Simeen Malik**

**Swapna Mahurkar**

**Fei Pan**

**Yaping Liu**

**Zack Ramjan**

**Jonathan Buckley**

**David Van Den Berg**

**Joe Aman**

**Philip Lai**

## COLLABORATORS

**Steve Baylin**

**Jim Herman**

**Leslie Cope**

**Kornel Schuebel**

**Ken Aldape**

## TCGA RESEARCH NETWORK

## FUNDING

**NIH/NCI**

**Canary Foundation**

**OCRF**

**CIRM**

**EIF**